Sudden Cardiac Arrest
0
Pipeline Programs
4
Companies
5
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Rhythm PharmaceuticalsBOSTON, MA
2 programsEP referred groupN/A1 trial
ICD or CRT-D DeviceN/A1 trial
Active Trials
Element BiosciencesCA - San Diego
2 programsJewel Patch Wearable Cardioverter DefibrillatorN/A1 trial
Jewel Patch Wearable Cardioverter DefibrillatorN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Element BiosciencesJewel Patch Wearable Cardioverter Defibrillator
Kestra Medical TechnologiesDefibrillation
Element BiosciencesJewel Patch Wearable Cardioverter Defibrillator
Rhythm PharmaceuticalsEP referred group
Rhythm PharmaceuticalsICD or CRT-D Device
Clinical Trials (5)
Total enrollment: 11,232 patients across 5 trials
The Jewel IDE Study
Start: Jan 2022Est. completion: Nov 2023322 patients
N/ACompleted
ASSURE WCD Clinical Evaluation - Post Approval Study (ACE-PAS)
Start: Nov 2021Est. completion: Oct 20255,179 patients
N/ARecruiting
Jewel Electrophysiology (EP) Lab Study
Start: Nov 2018Est. completion: Apr 202418 patients
N/ACompleted
Improve SCA Bridge Study
Start: Nov 2018Est. completion: May 20211,491 patients
N/ACompleted
Improve Sudden Cardiac Arrest Study
Start: Mar 2014Est. completion: Sep 20184,222 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 11,232 patients
4 companies competing in this space